Latest Articles

Publication Date
Onconic Therapeutics announced on the 28th that "Nesuparib," a candidate for a double-targeted antic.. - 매일경제

Onconic Therapeutics announced on the 28th that "Nesuparib," a candidate for a double-targeted antic.. 매일경제

Published: July 28, 2025, 6:56 a.m.
Universal Quantum Joins Institute To Advance Endometrius Therapeutics - Quantum Zeitgeist

Universal Quantum Joins Institute To Advance Endometrius Therapeutics Quantum Zeitgeist

Published: July 24, 2025, 11:09 a.m.
Endometriosis Therapeutics: A Market in Need, but Can Organon Still Lead? - AInvest

Endometriosis Therapeutics: A Market in Need, but Can Organon Still Lead? AInvest

Published: July 2, 2025, 1:04 p.m.
Womens Health Therapeutics Market to Reach USD 61.6 Billion by 2032, Driven by Innovation - newstrail.com

Womens Health Therapeutics Market to Reach USD 61.6 Billion by 2032, Driven by Innovation newstrail.com

Published: July 1, 2025, 10:45 a.m.
Women's Health Therapeutics Market Revenue to Attain USD 64.04 Bn by 2033 - Precedence Research

Women's Health Therapeutics Market Revenue to Attain USD 64.04 Bn by 2033 Precedence Research

Published: June 13, 2025, 1:43 p.m.
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - TradingView

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting TradingView

Published: June 2, 2025, 11:30 a.m.
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) The Manila Times

Published: May 27, 2025, 12:47 p.m.
Advanced Endometrial Cancer Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com

Advanced Endometrial Cancer Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Barchart.com

Published: May 20, 2025, 11:32 p.m.
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY - BioSpace

MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY BioSpace

Published: May 20, 2025, 12:52 p.m.
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY - PR Newswire

MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY PR Newswire

Published: May 20, 2025, noon
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!